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Abstract 
In 2013, the Centers for Disease Control and Prevention (CDC) declared 
antibiotic resistance a serious health threat to the global community.  Multi-drug resistant 
(MDR) Gram-negative bacteria have become particularly problematic, as very few new 
classes of small-molecule antibiotics for Gram-negative bacteria have emerged in recent 
decades. The Feldheim Lab has developed a combinatorial screening process for
identifying mixed-ligand monolayer gold nanoparticle conjugates with antibiotic activity. 
The gold nanoparticle conjugates have been found to be highly active against E. coli. The 
bacteria develop resistance to the nanoparticles at a significantly slower rate than 
commercially available small-molecule drugs. 
The Feldheim Research Team has shown that the antimicrobial property of the 
nanoparticles depends on the identity and ratio of the ligands in the monolayer. Altering 
the ratio of one of the ligands from a conjugate designed for E. coli produced an altered 
conjugate with high levels of activity towards K. pneumoniae, and turned a bacteriostatic 
conjugate into a bactericidal conjugate. The altered conjugate also doubled the time to 
resistance over the initial nanoparticle formulation.  
A differential gene expression experiment discovered that the altered conjugate 
affected a significantly increased number of genes compared to the original compound. It 
was determined that more active conjugates may alter the expression of many cell 
division proteins unchanged in the less active nanoparticles. In addition, the altered 
conjugate induced the expression of many antibiotic resistance genes, yet the bacteria 
remained susceptible to the conjugate for a number of days. The nanoparticle highly 
active toward K. pneumoniae was ineffective against M. avium and M. abscessus, 
possibly indicating bacterial specificity. The altered gold-nanoparticle conjugate was 
found to be an effective inhibitor of K. pneumoniae growth, with the possible ability to 
avoid resistance mechanisms. 
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I. Introduction 
Antibiotic Resistance and Klebsiella pneumoniae 
In 2013, the Centers for Disease Control and Prevention (CDC) declared antibiotic 
resistance a serious health threat to the global community.1 In the U.S. alone, at least two million
people are infected with antibiotic resistant bacteria every year and the contagions cause over 
23,000 deaths annually.1 In the 2013 Threat Report, CDC director Thomas Frieden examined the 
possibility of a post-antibiotic world, where minor cuts and injuries could be fatal due to the loss 
of antibiotic efficacy. Antibiotic resistance poses a large threat to modern society’s vast medical 
advances. The loss of antibiotic efficacy would undermine the ability to perform surgeries, or 
conduct life saving treatments such as cancer chemotherapy and organ transplants. However, the 
emergence of drug resistant pathogens, and the battle against them, is not recent news.  Examples 
of bacteria overcoming the effects of antibiotics have been reported since the introduction of 
antibiotics into society. Penicillin was discovered in 1929 by Sir Alexander Fleming, and 
released for clinical use in 1945.2 Reports of penicillin resistance in some strains of 
Staphylococci came within one year of clinical release.3 Within four years, 60 percent of British 
clinical isolates were penicillin resistant.3 Today, about 70 percent of hospital-acquired infections 
are resistant to at least one form of antibiotic.4 
Antibiotic resistance may be natural or acquired. Certain bacteria are inherently resistant 
to specific types of antibiotics. This natural resistance occurs in species that lack a target or 
transport system for the drug of interest. Antibiotic treatment can be made problematic if the 
bacteria have certain structural characteristics such as thicker cell walls or decreased expression 
of porins in the cell membrane.5 Antibiotic resistance can also be acquired through spontaneous 
genetic mutation. Approximately one in one-billion bacteria undergo a mutation that allows for 
resistance, but considering high growth rates and high absolute numbers of cells obtained during 
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an infection, the time for an antibiotic resistant mutation to develop is relatively small.5 
Antibiotics put selective pressure on the bacterial colonies, thereby inhibiting the sensitive 
colonies, while also allowing resistant mutants to grow and divide. Resistant traits are passed on 
to their progeny through vertical evolution, as well as horizontal gene transfer.5 Horizontal 
transfer of genetic information through plasmids allows resistant traits to be passed along within 
a single generation. 
Four major mechanisms of resistance can occur in bacteria. The most common mode of 
resistance is enzymatic inactivation of antibiotics.5 During enzymatic inactivation, cellular 
enzymes are modified to interact with an antibiotic in a way that renders the drug inactive.  This 
process is exemplified by some bacteria’s ability to alter Streptomycin, inhibiting the drug’s 
ability to bind to the ribosome, thereby allowing transcription to proceed.5 A second mode of 
resistance is the modification of the antibiotic target site, which removes the antimicrobial effect, 
and allows for proper bacterial growth.5 Examples of the second mode of resistance can be 
observed in the penicillin binding proteins (PBPs), which are essential to cell wall biosynthesis 
and proliferation of the bacteria.6 The PBPs catalyze the formation of peptidoglycan in the cell 
wall of bacteria.6 Penicillin, a beta-lactam antibiotic, binds to the PBPs and inhibits 
peptidoglycan cross-linking.7 The bacterium continues the dynamic process of cell wall renewal. 
Autolysis continues while cell wall formation is halted due to the antibiotic, ultimately 
weakening the cell wall. The destabilized cell envelope eventually bursts due to osmotic 
pressure.  However, methicillin resistant Staphylococcus aureus produces a new penicillin 
binding protein, PBP2, which has low affinity for beta-lactam antibiotics.8 PBP2 becomes the 
predominant PBP in the presence of beta-lactam antibiotics, and allows for cellular 
proliferation.8 In the third resistant mechanism, enzymes may be produced that degrade 
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antibiotics.5 This mode of resistance is seen in the carbapenemases. Carbapenems are beta-
lactam antibiotics, similar to penicillin, with broad-spectrum activity toward both Gram-positive 
and Gram-negative bacteria.9 The carbapenems permanently acylate the PBPs that catalyze the 
formation of peptidoglycan in the cell wall of bacteria, leading to cell lysis.9 The most 
widespread mechanism of carbapenem resistance is the production of carbapenemases by the 
bacteria.9 Carbapenemases are specific beta-lactamases, which are periplasmic enzymes, with the 
ability to hydrolyze the beta-lactam ring of carbapenems, altering the structure of the drug and 
rendering it ineffective.9 Efflux pumps are the fourth mechanism of resistance, which allow for a 
wide range of resistance.10 These high-affinity transport systems clear the antibiotic out of the 
bacterial cell, which is a major mode of resistance against tetracyclin antibiotics.10, 5 Together, 
these four key mechanisms of resistance have allowed bacteria to gain resistance to almost all 
commercially available antibiotics 
The CDC has identified three different classes of bacteria that have significant levels of 
resistance and the ability to become widespread throughout the population at an extremely fast 
rate. High consequence antibiotic-resistant threats have been labeled as ‘Urgent Health Risks’ by 
the CDC.1 These hazardous strains of bacteria include (1) Clostridim difficile, (2) cephalosporin-
resistant Neisseria gonorrhoeae, and (3) Carbapenem-resistant Enterobacteriaceae.1 The 
majority of the work described in this manuscript utilized Klebsiella pneumoniae, a member of 
the Enterobacterieae class. K. pneumoniae is a Gram-negative, encapsulated, rod-shaped 
facultative anaerobe.11 This bacterium causes pneumonia, bloodstream infections, surgical site 
infections, and meningitis.12 Some reported strains of Klebsiella have become resistant to every 
antibiotic commercially available.1 The carbapenem-resistant strains are of particular concern 
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due to the fact that carbapenems are generally last resort antibiotics.1 The carbapenem-resistant 
Klebsiella is responsible for 7,900 drug-resistant infections every year.1 
The fast rates of antibiotic resistance and multi-drug resistance have made the 
development of new antibiotics difficult. Between 1960 and 2000, there were only three new 
classes of antibiotics introduced in the medical community.13 This is problematic because 
bacteria are quickly gaining resistance to the available classes of antibiotics. Doctors and 
researchers alike have been working toward developing new antibiotic materials to overcome the 
increase in antibiotic resistance. In 2014, the discovery of oxadiazoles introduced a new class of 
antibiotics that inhibit the penicillin-binding protein PBP2a, thereby inhibiting penicillin-
resistant forms of bacteria.14 However, it is only a matter of time before the bacteria evolve 
beyond this type of antibiotic. It is evident that new classes of antibiotics, which avoid the 
various mechanisms of resistance, must be developed in order to combat the rise in antibiotic 
resistance. 
Interest in Gold Nanoparticles 
The search to find new classes of antibiotics has led researchers to look outside the 
classical, small molecule antibiotics, toward organic and inorganic nano-materials.15,16,17 A vast 
number of nanoparticles have been synthesized, predominately those made from noble metals 
such as gold. There is a large interest in utilizing gold nanoparticles because they provide non-
toxic transporters for drug and gene delivery applications.17 Gold nanoparticles are clusters of 
gold surrounded by a monolayer of selected ligands.17 The gold core is essentially inert, non-
toxic, and imparts stability to the assembly of molecules. The monolayer of ligands allows for 
tunable properties such as charge and hydrophobicity.17 An additional attractive property of the 
gold nanoparticles are their interactions with thiols. The attachment of ligands through sulfur 
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bonds has allowed the Feldheim Lab to select and attach molecules with a variety of properties to 
construct custom antibiotics. 
This experiment utilizes the thiol-protected gold nanoparticles as antibiotics with a 
variety of thiol-ligands. Gold was chosen for the nanoparticle core due to its ability to create a 
wide variety of sizes, ranging from 1 nm to 150nm.17 The Feldheim Lab has focused on 
nanoparticles with a diameter of 1 – 5 nm. The average core size can be adjusted by changing the 
preparative conditions, such as the gold:ligand ratio, the reaction temperature, and the reducing 
agent.18 Gold consistently produces monodispersed nanoparticles and has an easily exchanged 
surface monolayer, which allows for a wide diversity of nanoparticle conjugates. Mass 
spectrometry and x-ray crystallography data are available for various nanoparticles, including 
those with base aggregates of 25, 38, 102, and 144 molecules of gold.19,20,18,21 Au-25 and Au-38 
are about 1 nm in diameter, while Au-102 and Au-144 are 1.5 nm and 2.0 nm respectively. These 
gold nanoparticles were found to have true chemical formulas such as [Au144(SC6H4COOH)60] for 
Au-144.21 
During gold nanoparticle synthesis, AuCl4- salts are reduced with NaBH4 in the 
presence of a thiol capping ligand.19 Initial gold nanoparticles are capped with passivating 
ligands, which can subsequently be exchanged for other types of molecules. In this associative 
type place exchange reaction, incoming thiol ligands displace existing ligands, creating a mixed 
thiol monolayer surrounding the gold nanoparticle.22 The gold nanoparticles are stabilized by this 
organothiol shell.18 The thiol modification allows for the construction of libraries with large 
numbers of distinct gold-nanoparticle conjugates that can be screened for antibiotic activity. 
Gold nanoparticles have many attributes that distinguish them from the traditional, small 
molecule antibiotics. These characteristics make them good drug candidates to combat multi-
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drug resistant pathogens. Nanoparticles can be constructed in a range of sizes, allowing for 
variance and adaptation of the antibiotic. The methods for synthesizing the gold nanoparticles are 
easily reproducible and yield water-soluble compounds. This allows for simple production, 
storage, and delivery of the antimicrobial agent. In nanoparticle synthesis, two or more ligands 
can be attached to a single particle to create multivalent and multifunctional systems.23 Small 
molecule drugs often have short blood circulation half-lives, but conjugation to a nanoparticle 
can prolong the in vivo circulation time from several minutes to several hours.24 The increased 
blood circulation half-life of the gold nanoparticle conjugates would provide less frequent 
administration of the drug and more effective antimicrobial therapy. Small-molecule drugs often 
rely upon a single high-affinity contact to a microbial target, and are typically incapable of 
disrupting protein-protein interactions.23 Small-molecule drugs are also easily expelled from the 
microbial cell through efflux pumps.5 The diameter of the nanoparticles are slightly larger than 
drug efflux pumps, indicating the possibility of avoiding antibiotic resistance more effectively 
than traditional, small-molecule antibiotics.24 The size of the gold nanoparticles could also 
provide them with the ability to disrupt protein-protein interactions.25,26,27,28 These characteristics 
give the gold nanoparticles many possible advantages over small-molecule drugs. 
Gold Nanoparticle Background Information 
The Feldheim Lab aspires to utilize gold nanoparticles as antibiotics to combat multi-
drug resistant pathogens. In order to screen the nanoparticles for antibiotic activity, an initial 
library of conjugates was created using a Small-Molecule Variable Ligand Display (SMVLD) 
method. This library is a catalog of all the gold nanoparticle conjugates created, as well as their 
efficacy as an antibiotic agent against the bacteria of interest. The mixed monolayer gold 
nanoparticle combinatorial library was created on ~2.0 nm diameter gold nanoparticles coated 
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with para-mercaptobenzoic acid (pMBA).23 Place-exchange reactions subsequently substitute some 
of the para-mercaptobenzoic acid in the monolayer with varying thiols of choice. Figure 1.1 
illustrates a simplified model of the gold nanoparticles before and after the place exchange 
reactions with three thiol-ligands. 
Figure 1.1 Thiol-Ligands in Ternary Combination Replace pMBA Molecules in the 
Monolayer of the Gold Nanoparticle (Figure from Bresee, J.; Maier, K. E.; Melander, C.; Feldheim, D. L. 
Chem. Commun. 2010, 46, 7516–7518.) 
 The initial library utilized ten commercially available thiols, combined in groups of 
three, with varying feed ratios. The feed ratio is the stoichiometric molar ratio of ligand input to 
gold nanoparticle input. The combination and ratio of the different thiol ligands has been shown 
to be vital to the antimicrobial efficacy of the gold nanoparticles.29 The thiol-ligands have a range 
of attributes with varying Hydrogen-bond donors and acceptors, as well as 
hydrophilic/hydrophobic properties that may contribute to the antimicrobial nature of the gold 
nanoparticles. The chemical characteristics of the thiols can be found in Table 1.1, with the 
structures found in Figure 1.2. 
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Table 1.1 Thiol Name and Chemical Characteristics 
Figure 1.2 Structure of Thiol Ligands 
The number of diverse compounds produced in a library can be calculated using the 
formula: !"#$%&  !"  !"#$"%&'( = (!!)/ !! ! − ! !
where m = number of thiols in the library and n = number of thiols in the exchange reaction. 
Thiol 
Number Thiol Name Characteristic 
1 3-Nitrobenzyl merceptan Hydrophobic 
2 3-methyl - 1 - butanethiol Hydrophobic 
3 4-mercaptophenol Antimicrobial, Amino Acid Structure 
4 4-aminothiophenol Hydrophobic 
5 Glutathione Water Soluble, Amino Acid Structure 
6 Cysteamine Amino Acid Structure, Hydrophobic 
7 Thioglucose Sugar Structure 
8 3-mercapto-1-propanesulfonic acid Water Soluble 
9 2 - diethylaminoethane thiol Hydrophobic 
10 N-(methyl) mercaptoacetamide Hydrophobic 
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The initial library of ten thiols, combined in groups of three, produced 120 distinct 
nanoparticle conjugates, many of which had antimicrobial properties.23  
 After the initial library construction, additional ligands such as thiol 11 were added for 
expanded diversity. Antimicrobial cationic peptides are well documented as part of the innate 
immune system of eukaryotes as a defense against pathogens.30 The positive charge on molecules 
such as arginine, lysine, and histidine have been found to interact with the negatively charged 
bacterial membrane. Thiol 11 is 3-(1H-imidazol-4-yl)-2-(((5-mercapto-3-
oxopentyl)oxy)amino)propanoic acid, and is similar in structure to the amino acid histidine with 
a short polyethylene glycol linker. The structure of ligand 11 can be seen in Figure 1.3. 
Figure 1.3: Structure of Thiol 11 -  A Thiolated Histidine Molecule 
(Histidine Structure in Brackets) 
 Several different nanoparticle conjugates in the library were found to be potent growth 
inhibitors of Escherichia coli (ATCC 25922).29 Table 1.2 highlights gold nanoparticles of 
interest that inhibit E. coli, the combination of thiol ligands, and the concentration of 
nanoparticles required to inhibit 99.9% of bacterial growth (MIC99.9), determined by plating and 
colony count.29 The nanoparticles reported in Table 1.2, particularly LAL-32, have high bacterial 
inhibition rates and have formed the foundation of this honors thesis. 
HS N
H
O
O
O
O N
H
OH
O O
O
N
HN
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Table 1.2 List of Gold Nanoparticle Conjugates and MIC99.9 Values for the Inhibition of E. 
coli (ATCC 25922). (Figure from Bresee, J.; Melander, C.; Feldheim, D. L. J. Am. Chem. Soc. 2014, 136, 
5295–5300.) 
Conjugate ID Thiol A Thiol B Thiol C MIC99.9 (μM) 
LAL-32 5 6 8 0.25 
LAL-33 6 8 9 0.5 
LAL-42 6 8 - 0.5 
LAL-52 5 6 11 0.25 
The LAL gold nanoparticle conjugates contain a monolayer of designated thiol ligands 
mixed with pMBA. The pMBA-capped nanoparticles with no additional thiol ligands were found 
to have no significant inhibitory activity at concentrations tested up to 50 μM. These tests 
confirm the thiol ligands provide antibiotic activity to the gold nanoparticles.29 The experiments 
also showed that the ligands must be bound to the surface of the nanoparticle to be active.29 The 
conjugate LAL-32 was experimentally determined to be approximately 360x more active per 
ligand than its corresponding free ligands (5, 6 and 8).29 This free-ligand experiment 
demonstrated that the gold nanoparticle conjugated to the mixed-ligand monolayer acts as a 
single entity antibiotic. The gold nanoparticle antibiotics contrast nanoparticle delivery systems 
previously utilized in the field. Solid-state Nuclear Magnetic Resonance (NMR) spectroscopy 
confirmed the conjugation of pMBA and the thiol ligands to the active gold-nanoparticle, thus 
verifying the presence of a mixed monolayer.23  
Detailed characterization of the nanoparticles was important to determine how the 
nanoparticles may be interacting with the bacteria. For example, LAL-32, found to be one of the 
most potent inhibitors of E. coli growth, contains a core diameter of 2.4 nm ± 0.6 nm.29 This is a 
slight increase over the pMBA-capped gold nanoparticle starting material, which had a diameter 
of 2.2 nm ± 0.4 nm.29 The diameter of the nanoparticle is particularly important in bacterial 
studies as it determines the scale on which the drug can interact with the bacteria, as well as if 
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the bacteria can easily excrete the molecule. It was estimated that on average, the monolayer of 
LAL-32 contains 11 p-mercaptobenzoic acids, 33 glutathiones (5), 28 cysteamines (6), and 15 3-
mercapto-1-propanesulfonic acids (8).29  
Several experiments were performed to help elucidate the mode of action of the 
nanoparticles.  A BacLight Permeability assay performed with LAL-32 showed that membrane 
disruption did not occur in the E. coli strain tested.29 Experiments revealed that the nanoparticle 
conjugates are generally not cytotoxic, nonspecific cell membrane disruptors, but rather affect 
the transcription of several genes.29 This data is important because it confirmed the nanoparticles 
are not “nuisance compounds.” Nuisance compounds are molecules that act equally on bacterial 
and mammalian cells, and are detrimental to all cell types. The gold nanoparticles selectively 
inhibit bacterial cell growth, which allows for possible use as an antibiotic in vivo. Transmission 
Electron Microscopy experiments with E. coli showed internalization of nanoparticles into the 
cell, indicating the ability to reach intercellular targets.29 Figures 1.4 and 1.5 show E. coli cells 
incubated with conjugate LAL-32 for one hour and six hours respectively, effectively 
demonstrating the nanoparticle conjugates internalization into the cell. 
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Figure 1.4: Transmission electron microscope images of sectioned (~60 nm) E. coli 
incubated with LAL-32 for 1 hr. The red arrows indicate nanoparticles; the yellow arrows 
indicate bacteria membrane.  (Figure from Bresee, J.; Melander, C.; Feldheim, D. L. J. Am. Chem. Soc. 
2014, 136, 5295–5300.) 
Figure 1.5: Transmission electron microscope images of sectioned (~60 nm) E. coli cells 
incubated with LAL-32 for 6 hr. The red arrows indicate nanoparticles; the yellow arrows 
indicate bacterial membrane. (Figure from Bresee, J.; Melander, C.; Feldheim, D. L. J. Am. Chem. Soc. 
2014, 136, 5295–5300.) 
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The gold nanoparticles’ ability to reach intracellular targets led to gene expression 
experiments to further elucidate the mode of action. The genetic pathways most altered may 
indicate how the gold nanoparticles were affecting the bacteria. E. coli samples were incubated 
with pMBA only nanoparticles (control sample), as well as active LAL-32 conjugates. The RNA 
was then extracted and analyzed to determine which genes had been upregulated/downregulated 
when exposed to either treatment. Microarray experiments found 154 genes that were 
differentially expressed in E. coli upon exposure to LAL-32 compared to untreated cells.29 
Evidence showed an up-regulation of genes encoding for metabolic pathway components, efflux 
pumps, membrane proteins, and multiple antibiotic resistance genes (mar) upon exposure to 
active gold nanoparticle conjugates.29 The mar gene products confer resistance to many 
structurally unrelated small-molecule drugs, including chloramphenicol, fluoroquinolones, and 
tetracycline.31 The mar-associated resistance occurs through increased production of efflux 
pumps to excrete the small-molecule drugs.31 The up-regulation of mar genes in the bacteria did 
not diminish the inhibitory effects of LAL-32. This indicated that the intrinsic cellular machinery 
in E. coli to confer antibiotic resistance was not adequate to counteract the effects of the 
nanoparticle. 
The gene expression experiment also determined that gold nanoparticle exposure caused 
a down-regulation in many transcriptional regulators and cell division proteins.29 DicC 
specifically was down-regulated upon exposure to LAL-32 compared to the pMBA-capped gold 
nanoparticle.29 DicC is involved in the control of cell division, including activation of the Min 
family of proteins, which regulate the location of FtsZ polymerization.32,33 Most bacterial cell 
division is initiated by the formation of the Z-ring, which consists of a dynamic structure of FtsZ 
polymers.34 The Z-ring’s location is determined by negative regulators of FtsZ assembly, which 
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recruits additional division proteins to form the septal ring, separating the two progeny cells.35 
The septum occurs in the area where the concentration of these negative regulators is at a 
minimum. Experiments showed that the gold nanoparticle conjugate LAL-32 down-regulates 
some of these negative regulators and therefore may affect proper formation of the Z-ring during 
cell division.29  
Gold Nanoparticles As Antibiotics 
The Feldheim Research Group has demonstrated that nanoparticle activity depends on the 
specific combination of ligands attached to the particle surface. Some of the most potent 
nanoparticle conjugates inhibit 99.9% of E. coli growth at a minimum inhibitory concentration 
(MIC99.9) of 250 nM.29  LAL-32 and LAL-52 are therefore more potent antibiotics than many 
small-molecule antibiotics on the market currently, such as ampicillin (MIC of 11 µM), 
gentamicin (MIC of 1 µM), and chloramphenicol (MIC 12 µM).36,37  
The emergence of multi-drug resistant pathogens has made developing antibiotics that 
avoid or increase the time to resistance of great importance. Experiments have shown that E. coli 
developed resistance against the nanoparticles significantly slower than chloramphenicol, a 
commercially available small-molecule drug.29 Even after 50 days of exposure, E. coli was not
able to gain significant resistance to the gold nanoparticle conjugate LAL-32.29 In contrast, E. 
coli was able to develop resistance to chloramphenicol within two days of exposure.29 The time 
to resistance had significant variance between conjugates, and was dependent on the identity and 
ratio of the thiol ligands in the mixed monolayer.  The nanoparticles have the potential to greatly 
reduce the speed at which pathogens gain resistance to antibiotics. This feature increases the 
potential to treat multi-drug resistant pathogens with gold nanoparticles, combatting the global 
issue of antibiotic resistance. 
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The Feldheim Lab has performed numerous experiments to determine the potential use of 
gold nanoparticles as drugs in vivo. Blood hemolysis assays performed on defibrinated sheep 
blood cells found that within experimental error, no hemolysis was observed for LAL-33, LAL-
42, or LAL-52 even at 100x the MIC99.9.29 This indicates that there was high selectivity of the 
active nanoparticle conjugates for bacterial cell growth inhibition over mammalian cell 
hemolysis. MTT toxicity assays also established that the gold nanoparticle conjugates were not 
toxic to human liver cells (HepG2/2.2.1, ATCC CRL -11997) in concentrations up to 0.8 μM.29
The Feldheim Research Team demonstrated that the in vivo biodistribution, clearance, and 
toxicity of ligand-modified gold nanoparticles depend on the ligands in the monolayer, which 
enables them to be easily adjusted. Glutathione-modified gold nanoparticles are primarily cleared 
through the renal system, and do not cause any toxicity or morbidity.38,39 Although the LAL-32 
conjugate behaved similarly to the glutathione-modified nanoparticles at low concentrations (10 
μM), it caused renal complications at higher concentrations (60 μM).29 By adding a thiolated 
oligoethyleneglycol into the mixed monolayer of LAL-32, the nanoparticle LAL-32EG was 
produced, which showed no in vivo toxicity at high concentrations, and maintained an identical 
bacterial growth inhibition efficacy.29  
The Feldheim Lab injected mice with 200 μL of 60 μM LAL-32EG, and found the 
nanoparticles were cleared primarily through the kidneys, and blood circulation half-life was 
estimated to be 7 hours ± 3 hours.29 Furthermore, the addition of polyethylene glycol (PEG) into 
the monolayer of the nanoparticle dramatically enhanced the absorption of the gold nanoparticles 
in the gastrointestinal tract.29 This information demonstrated that the mixed thiol monolayer gold 
nanoparticles are possible candidates for novel orally bioavailable antibiotics. 
16	  
The Feldheim Lab utilized E. coli to demonstrate the gold nanoparticles’ potential as an 
antibiotic. The same Small Molecule Variable Ligand Display (SMVLD) method of developing 
gold nanoparticles that inhibit the growth of E. coli, can also be utilized to find potent inhibitors 
of other bacteria of interest, such as Klebsiella pneumoniae. It is particularly important to find 
antibiotics that are active against Klebsiella pneumoniae and also avoid resistance mechanisms. 
Early in 2015, two deaths, seven confirmed infections, and 179 possible exposures to 
Carbapenem-Resistant Enterobacteriaceae (CRE) were reported in a Los Angeles hospital.40 The 
CRE are resistant to all, or nearly all, available antibiotics, including the most powerful drugs of 
last-resort.41 The CDC has warned that the CRE are spreading in hospital settings, and have 
reported a 50% death rate among patients who acquire a CRE bloodstream infection.41 This 
honors project aimed toward finding a highly potent gold nanoparticle conjugate that is effective 
against Klebsiella pneumoniae,  while overcoming potential antibiotic resistance. 
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II. Methods
Synthesis of pMBA- Capped 2.0 nm Gold Nanoparticles 
The two nanometer diameter [Au144(SC6H4COOH)60] gold nanoparticles were 
synthesized in a three-day process, previously described by the Feldheim Lab.1 
Approximately 136 mg of HAuCl43H2O (Sigma-Aldrich) was dissolved in 20 mL of 
methanol at room temperature with constant stirring in a 50 mL Erlenmeyer flask. 
Simultaneously, 210 mg of para-mercaptobenzoic acid (pMBA) (TCI-America) was then 
dissolved in 15.4 mL of ultrapure H2O and 0.6 mL of 10 M NaOH. The pMBA solution 
was then added to the gold/methanol solution and covered with parafilm. The solution 
was allowed to react overnight with constant stirring. 
After 16 to 18 hours, the solution was divided equally between three 500 mL 
Erlenmeyer flasks, followed by the addition of 62 mL of methanol and 178 mL of 
ultrapure H2O to each flask. A 0.25 M solution of sodium borohydride (Sigma Aldrich) 
was freshly prepared and 2.4 mL were immediately added to each flask. Adding 24 mL 
of ultrapure H2O further diluted each solution. The nanoparticle formation reaction was 
allowed to react for 24 hours with constant stirring.  
After 24 hours, the gold nanoparticles were harvested. The addition of 2 mL of 
5.0 M NaCl and 150 mL of methanol to each flask caused nanoparticle precipitation. The 
nanoparticles were then pelleted by centrifugation at 3200x g for 5 minutes in 50 mL 
conical tubes. The pellets were dried overnight, and subsequently re-suspended in filter-
sterilized ultrapure H2O. The gold nanoparticles were then washed on 10k M.W.C.O. 
filters (Millipore) with filter-sterilized ultrapure H2O and centrifuged five times for 6 
minutes at 3200x g, followed by a sixth round for 8 minutes at 3200x g. Nanoparticle 
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concentration was determined through UV-visible spectroscopy using the ε510nm of 
409,440 M-1cm-1.  
The source and age of the reagents in gold nanoparticle synthesis are important in 
preparation, as well as efficacy of the antimicrobial properties. It should be noted that 
reagents should not be stored with other chemicals that could cause contamination. 
Place Exchange Reactions 
Place-exchange reactions were performed to swap various pMBA molecules with 
thiol ligands of interest on the surface of the gold nanoparticles. One-pot place-exchange 
reactions were conducted with 7.4 μM gold nanoparticles in 4 mL of sterilized 20 mM 
Na2HPO4 pH 9.5 in 15 mL conical centrifuge tubes. The thiol ligands were then added to 
the gold nanoparticles in specific molar feed ratios. The nanoparticles used as the 
foundation of this experiment utilized thiols 5, 8, and 9 in 33x molar excess of the gold 
nanoparticles. Thiol-6 was utilized at 46x molar excess and thiol-11 was used in 16.5x 
molar excess. These are the feed ratios utilized in the exchange reactions unless otherwise 
specified. The thiols were stored at -80°C at 20 mM in water, except for thiol 11, which 
was stored in DMSO. The solutions of gold, thiol ligands and Na2HPO4 were mixed and 
agitated on a plate shaker for 24 hours at 19°C.  
The exchanged product was harvested through the addition of 2 mL of 5.0 M 
NaCl and 9 mL of methanol. The conical tubes were then centrifuged at 3200x g for 20 
minutes. The supernatant was discarded, and the pellet was re-suspended in 4-6 drops of 
filter-sterilized ultrapure H2O. The nanoparticles were then precipitated again by the 
addition of 500 μL of 5.0 M NaCl and 8 mL of methanol to each hydrated pellet, 
followed by centrifugation at 3200x g for 10 minutes. After discarding the supernatant, 
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the pellet was allowed to dry to completion overnight. 
After 24 hours, the pellet was re-suspended in filter-sterilized ultrapure water, 
before being washed over a 10k M.W.C.O. filter (Millipore) to remove excess salt and 
free thiol ligands. The particles were washed eight times for 4 minutes at 12,000x g. 
Particle concentration was determined through UV-visible spectroscopy (ε510nm = 409,440 
M-1cm-1).  
Growth Inhibition Assay 
All bacterial experimentation was performed in a SterilGard III Advance0 Class II 
Biological Safety Cabinet to drastically decrease the potential of contamination. Cultures 
of the bacteria were generated by touching the top of four well-isolated colonies of the 
bacteria of interest from an agar plate with a pipette tip and grown in 3 mL of broth. The 
bacteria utilized in this experiment were Escherichia coli (ATCC 25922), which had been 
grown in Mueller-Hinton broth (Fisher); Klebsiella pneumoniae (ATCC BAA 2146), 
grown in Mueller-Hinton II cation-adjusted media (Fisher); Mycobacterium avium (MAC 
104WT); and Mycobacterium abscessus (ATCC 19977), grown in Middlebrook 7H9 
Broth (Fisher). 
Cultures were grown at 37°C and 225 rpm, until visible turbidity was reached. 
The initial culture incubation period was 4 hours for E. coli, 12 hours for K. pneumoniae, 
24 hours for M. abscessus, and 72 hours for M. avium. After the incubation period, the 
bacteria cultures were diluted to 2 x 106 CFU/mL. The bacterial concentration was 
determined using UV-Visible Spectroscopy where an OD600 of 0.001 is assumed to be 
approximately 1x106 CFU/mL. The nanoparticle samples were diluted to the desired 
testing concentration with the correct broth for the specific bacterium. Equal volumes of 
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nanoparticle and inoculation sample were mixed, which made the final bacteria 
concentration 1 x 106 CFU/mL. Samples were then incubated at 37°C and 225 rpm. The 
growth inhibition incubations times were 18 hours for E. coli, 24 hours for K. 
pneumoniae, 72 hours for M. abscessus, and 168 hours for M. avium.
Percent inhibition was determined by serially diluting cultures in 1x PBS and 
plating on Mueller-Hinton agar plates for E. coli, Mueller-Hinton II plates for K. 
pneumoniae, and Middlebrook 7H10 agar plates for M. abscessus and M. avium. The 
plates were incubated at 37°C for the same amount of time as the growth inhibition 
incubation times indicated for the specific bacterium. The MIC99.9 was defined as the 
minimum nanoparticle concentration that inhibits 99.9% of bacterial growth, which was 
determined by colony counting. 
Resistance Assays 
A resistance assay was performed with varying gold nanoparticle conjugates. An 
overnight culture of Klebsiella pneumoniae (ATCC BAA 2146) was grown by touching 
the tops of four well-isolated colonies of bacteria with a pipet tip from a plate of Mueller-
Hinton II agar and grown in 3 mL of Mueller-Hinton II broth. This culture was allowed 
to grow for 24 hours before being diluted to 2x106 CFU/ mL in Mueller-Hinton II broth. 
The nanoparticles of interest were diluted in Mueller-Hinton II broth so that 1 x 106 
CFU/mL of bacteria would be incubated in the final volume with 60% of the MIC99.9. 
Equal volumes of nanoparticle and bacteria were combined and incubated at 37°C and 
225 rpm. The same sample of bacteria was serially passed every 24 hours by taking 5 μL 
of bacteria and adding it to 500 μL of fresh broth with an additional treatment of 60% of 
the MIC99.9 of nanoparticle. 
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pMBA-capped nanoparticles were serially passed to determine if the bacteria 
continually exposed to the pMBA-capped conjugates remained sensitive to the active 
conjugates. The pMBA-capped nanoparticles were found to have no antimicrobial 
properties at any concentration tested (up to 50 μM)1, and therefore do not have an 
MIC99.9.  As a consequence, it was arbitrarily assigned that 10 μM of the pMBA would be 
passed every 24 hours. A bacteria-only (no nanoparticle treatment) negative control was 
also carried through the passages. 
The minimum inhibitory concentration was tested at various times during the 
resistance assay to monitor the MIC99.9 of the nanoparticle compounds. Bacterial 
resistance to the nanoparticle conjugates was defined as an increase in the MIC99.9 to 10x 
the original MIC99.9. The lower concentrations tested (1x, 2x, and 5x MIC99.9) also had to 
fail to produce 99.9% inhibition for resistance to be confirmed, thus ruling out 
experimental error. 
Gene Expression Profiling 
A 4 mL overnight culture of K. pneumoniae (ATCC BAA 2146) was diluted into 
75 mL of Mueller-Hinton II broth, and grown to OD600 = 0.7. The bacteria culture was 
divided into fifteen 4 mL cultures, in 25 mL Erlenmeyer flasks. An additional 2 mL of 
Mueller-Hinton II broth was added to each culture. The three active nanoparticle 
conjugates tested and pMBA-capped gold nanoparticles (all repeated in triplicate) were 
added to a final concentration of 6.25 μM. “Bacteria only” (containing no nanoparticle 
conjugate) controls were also run in triplicate. The samples were incubated at 37°C and 
225 rpm for 4 hours, and then 2 mL of each sample were used for RNA extraction. 
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The nanoparticle conjugate samples were washed with 1x PBS, followed by 
centrifugation at 3200x g for 2 minutes to remove the nanoparticle conjugates from the 
cell pellet. Total RNA was extracted from the samples using the Bio-Rad Aurum Total 
RNA Mini-Kit.  RNA extraction was confirmed by running the samples on a 1.0% TBE 
agarose gel, and then visualized by ethidium bromide staining. A Quick-Load 2-Log 
DNA Ladder (0.1 – 10.0 kb) (New England Biolabs) was used to check the presence of 
the 16s and 23s rRNA bands.  The quality of RNA was confirmed using an Agilent 2100 
Bioanalyzer and Agilent RNA 6000 Nano Chips at the Next-Generation Sequencing 
Facility, Biofrontiers Institute of the University of Colorado. The total RNA samples 
were then frozen and shipped on ice to BGI Americas Corporation (Cambridge, MA) for 
mRNA isolation and RNA-Seq Transcriptome Resequencing. 
BGI first removed rRNA, then fragmented the mRNA, and finally synthesized the 
cDNA using the mRNA as a template.  The suitable fragments were amplified using 
Polymerase Chain Reaction (PCR) and sequenced with an Illumina HiseqTM 2000 
sequencing platform with single-end 50 bp reads. The sequences data was aligned with 
the reference sequence using SOAPaligner/SOAP2. Bioinformatics, including a 
differential gene expression analysis, Gene Ontology (GO) enrichment analysis, and 
pathway enrichment analysis was performed by BGI Americas Corporation. 
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III. Results and Discussion
Discovering Gold Nanoparticle Conjugates Active Toward K. pneumoniae 
This honors project aimed at finding gold nanoparticle conjugates that were 
effective inhibitors against Klebsiella pneumoniae (ATCC BAA 2146). Nanoparticle 
conjugates previously found by the Feldheim Lab to be potent inhibitors of Escherichia 
coli (ATCC 25922) growth were initially tested as candidates. Because both strains of 
bacteria are Gram-negative members of the Enterobacteriaceae family, their responses to 
antibiotics were likely to be similar. The main differences between the two bacteria 
species is the thick coat of extracellular polysaccharide of Klebsiella pneumoniae called a 
“capsule” that helps protects the cells from desiccation and phagocytosis when inside an 
animal host.1 The capsule that K. pneumoniae produces has been shown to provide 
resistance to antimicrobial peptides and proteins, and reduces cell membrane penetration 
by some antibiotics.2,3 This specific strain of K. pneumoniae also expresses New Delhi 
Metallo-β-lactamase (NDM-1), an enzyme that confers resistance to beta-lactam 
antibiotics including last-resort Carbapenems.4 The NDM-1 is encoded by the blaNDM 
gene (associated with a plasmid) and is transmissible through horizontal gene transfer.5 
The E. coli strain primarily used in previous gold nanoparticle experiments displayed 
sensitivity to every type of antibiotic tested, including some beta-lactams.5  
The high efficacy of conjugates LAL-32, LAL-33, LAL-42, and LAL-52 (Table 
1.2) toward E. coli growth inhibition made them desirable candidates to be tested against 
K. pneumoniae. Experimentation found each of these four particles to be an effective 
inhibitor against K. pneumoniae, with a slightly increased Minimum Inhibitory 
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Concentration (MIC99.9) that reduced bacterial growth by 99.9%. Table 2.1 reports the 
MIC99.9 for the tested nanoparticles for both E. coli6 and K. pneumoniae.
Table 2.1: MIC99.9 values for various gold nanoparticle conjugates against E. coli 
and K. pneumoniae as determined by colony counting. E. coli MIC99.9 values reported 
from J. Am. Chem. Soc. 2014, 136, 5295–5300.  
Nanoparticle 
Conjugate 
MIC99.9  
(E. coli) μM6
MIC99.9  
(K. pneumoniae) μM 
LAL- 32 0.25 0.625 
LAL- 33 0.5 1.25 
LAL- 42 0.5 1.25 
LAL- 52 0.25 0.625 
The efficacy of the gold nanoparticles conjugate depends on precise synthesis, 
including the integrity of the chemical agents. In addition, the percent inhibition of the 
conjugates varies slightly between batches. The reported MIC99.9 values in Table 2.1 were 
found to consistently inhibit at least 99.9% of bacterial growth. 
Altering the Active Conjugate to Increase K. pneumoniae Growth Inhibition 
LAL-32 consisted of ligands 5, 6, and 8 (Table 1.1) with feed ratios of 33x, 46x, 
and 33x respectively. LAL-52 contained ligands 5, 6, and 11 with feed ratios of 33x, 46x, 
and 16.5x respectively. These two conjugates were found to be the most effective 
inhibitors of K. pneumoniae. The Feldheim Lab previously proved that the antimicrobial 
activity of the gold nanoparticle conjugates was dependent on the feed ratio of the various 
ligands in the monolayer.6 Therefore, it was hypothesized that altering the feed ratios of 
one of the existing E. coli conjugates could produce a more active nanoparticle against 
Klebsiella pneumoniae.  
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LAL-32 was chosen as the conjugate to be altered in this experiment due to the 
lower MIC99.9, which indicated a higher efficacy of inhibition, as well as the relatively 
easy obtainment of ligand 8 compared to ligand 11 in high quantities. The search for 
optimizing feed ratios began by multiplying the existing feed ratios (33x, 46x, 33x) of 
one or two of the ligands by factors such as 0.75 or 1.25, and testing the resulting 
conjugate for activity. The subsequent conjugates were tested against K. pneumoniae at 
0.625 μM and 1.25 μM. Presumably, if the MIC99.9 increased by more than 2-fold, the 
altered feed-ratio conjugate would not be an improvement over the original formulation, 
and therefore should not be kept as a K. pneumoniae inhibitor candidate. 
The nanoparticle-exposed bacterial cultures were analyzed visually for turbidity 
after 24 hours. Plating and colony counting were utilized to determine the logs of 
inhibition if the cultures were found to be clear. The logs of inhibition were determined 
using the formula: 
!"#  ( !"#"$%  !"#$%&'  !"#$%  !"#ℎ  !"#$!%#&!!"#"$%  !"#$%&'  !"#$%  !"#ℎ  !"  !"#$!%#&!) 
    where 3 logs of inhibition is equal to 99.9%, 4 logs of inhibition = 99.99%, etc. 
Table 2.2 illustrates the results obtained from the altered feed ratio experiment.  
30 
Table 2.2 : The Feed Ratio of thiol ligands in the altered feed ratio conjugates, the 
resulting turbidity at 0.625 μM and 1.25 μM, as well as the logs of inhibition at 
0.625 μM if applicable.  Error in the logs of inhibition was calculated by plating and 
colony counting in triplicate and calculating the standard deviation 
Gold 
Nanoparticle 
Conjugate 
Feed 
Ratio 
of 5 
Feed 
Ratio 
of 6 
Feed 
Ratio 
of 8 
Turbidity at 
0.625 μM  
Turbidity at 
1.25 μM 
Logs of 
Inhibition at 
0.625 μM 
LAL-32 33 46 33 clear clear 3.45 ± 0.36 
LAL-32 a 16.5 46 33 turbid turbid n/a 
LAL-32 b 33 23 33 turbid turbid n/a 
LAL-32 c 33 46 16.5 clear clear 3.17 ± 0.31 
LAL-32 d 41.25 33 46 turbid turbid n/a 
LAL-32 e 49.5 33 46 clear clear 4.14 ± 0.48 
LAL-32 f 33 33 57.5 turbid clear n/a 
LAL-32 g 33 33 69 clear clear 4.66 ± 0.52 
LAL-32 h 33 41.25 46 turbid turbid n/a 
LAL-32 i 33 49.5 46 turbid turbid n/a 
LAL-32 j 33 33 33 clear clear 4.53 ± 0.42 
LAL-32 k 46 46 46 clear clear 3.51 ± 0.47 
LAL-32 L 49.5 46 33 clear clear 1.90 ± 0.12 
LAL-32 m 33 69 33 turbid turbid n/a 
LAL-32 n 33 46 49.5 turbid turbid n/a 
Three altered feed ratio conjugates, LAL-32 e, LAL-32 g and LAL-32 j, were 
found to inhibit the growth of K. pneumoniae more effectively than the original LAL-32 
conjugate, and were therefore selected for further testing. Serial dilutions ranging from 20 
μM to 0.04 μM of the conjugates were incubated with the bacteria to test for the MIC99.9. 
Table 2.3 reports the logs of inhibition determined by plating and colony counting for 
selected concentrations near the transition from turbid to clear for the bacterial cultures. 
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Table 2.3: The logs of inhibition for selected gold nanoparticle conjugates at 0.313 
μM, 0.625 μM, and 1.25 μM, as determined by plating and colony count. Error in the 
logs of inhibition was calculated by plating and colony counting in triplicate and 
calculating the standard deviation.  
Nanoparticle 
Conjugate 
Logs of Inhibition at 
0.313 μM 
Logs of Inhibition at 
0.625 μM 
Logs of Inhibition at 
1.25 μM 
     LAL-32 2.87 ± 0.29 3.45 ± 0.36 3.74 ± 0.38 
LAL-32 e 2.74 ± 0.37 4.14 ± 0.48 4.53 ± 0.23 
LAL-32 g 1.89 ± 0.21 4.66 ± 0.52 7.66 ± 0.56 
LAL-32 j 2.16 ± 0.25 4.53 ± 0.42 7.50 ± 0.47 
Experimentation revealed that conjugates LAL-32 g and LAL-32 j were capable 
of inhibiting approximately seven logs of inhibition at the concentrations tested. LAL-32 
and LAL-32 e did not appear to reach that efficacy of inhibition at any concentration 
tested. It should be noted that at high concentrations (above 12 μM), the nanoparticles 
appeared to lose efficacy and the cultures were turbid. This phenomenon may be due to 
aggregation of the nanoparticles in the nutrient broth. 
 The Feldheim Lab defines nanoparticles that inhibit more than 5 logs or 99.999% 
growth versus the untreated control to be bactericidal, making conjugates LAL-32 g and 
LAL-32 j bactericidal compounds.7 Bactericidal antibiotics are defined by the ability to 
kill microbes, while bacteriostatic antibiotics inhibit growth.8 Experimentation suggests 
that LAL-32 g and LAL-32 j become bactericidal at higher concentrations, while LAL-32 
and LAL-32 e remain bacteriostatic at all concentrations. Table 2.4 reports the defined 
MIC99.9 and the Minimum Bactericidal Concentration (MBC) for conjugates LAL-32, 
LAL-32 e, LAL-32 g, and LAL-32 j.  
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Table 2.4: The defined MIC99.9 and MBC for selected gold nanoparticle conjugates. 
Nanoparticle Conjugate MIC99.9 MBC 
LAL-32 0.625 μM n/a 
LAL-32 e 0.625 μM n/a 
LAL-32 g 0.625 μM 1.25 μM 
LAL-32 j 0.625 μM 1.25 μM 
This experiment showed that altering the feed ratio of the thiol ligands in the 
monolayer of a gold nanoparticle could drastically alter the inhibitory efficacy, and 
change a bacteriostatic conjugate into a bactericidal conjugate. 
Determining the Time to Resistance for K. pneumoniae 
A resistance assay was performed on the K. pneumoniae bacteria to investigate 
how the altered feed ratio conjugates would affect the time to resistance. The bacteria 
were incubated with 60% of the MIC99.9 and serially passed until resistance was achieved. 
Resistance was defined when the MIC99.9 was increased to 10 times the original MIC99.9. 
All lower concentrations tested must have also failed to produce 99.9% inhibition for 
resistance to be confirmed. 
The nanoparticle conjugates selected for resistance testing were LAL-52, LAL-
32, LAL-32 g, and LAL-32 j due to high antimicrobial efficacy. Resistance assays were 
also conducted on two different antimicrobial treatments that were alternated every 24 
hours to determine if rotating exposures could help extend the time to resistance. 
Treatments of LAL-52 and LAL-32 were alternated every day to determine the time to 
resistance of alternating exposures.  In a separate trial, treatments of LAL-32 g and LAL-
32 j were also alternated every day. The pMBA-capped nanoparticles were passed 
alongside the active conjugates to determine if the bacteria continually exposed to the 
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gold core would remain sensitive to the active conjugates. The results of the resistance 
assay are presented in figure 2.1. 
Figure 2.1: The average days to resistance for K. pneumoniae treated with 60% of 
the MIC99.9 of various gold nanoparticle conjugates. The average days to resistance 
were calculated based on two different resistance assays and the error bars represent the 
upper and lower limits of the two resistance assays.  
K. pneumoniae developed resistance to the original LAL-32 compound at a fairly 
quick rate (4 days). The LAL-32 g and LAL-32 j compounds both increased the time to 
resistance over the original compound LAL-32. LAL-32 j increased the time to resistance 
more than 2-fold over the original compound. By alternating between two different 
compounds, an intermediate time to resistance was produced. The bacteria were sensitive 
to conjugate LAL-52 for the longest duration, having a three-fold increase in time to 
resistance over LAL-32. The single difference between LAL-32 and LAL-52 was the 
exchange of ligand 8 for ligand 11. This exchange indicated that the thiol ligands in the 
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monolayer of the gold nanoparticle conjugates altered the time to resistance significantly. 
Therefore, the conjugates could potentially be improved to further avoid antibiotic 
resistance. 
Bacteria that were serially passed in the presence of the pMBA-capped gold 
nanoparticles for 12 days remained sensitive to the active conjugates. The experimental 
evidence showed that the bacteria did not become resistant to the gold core, but did 
become resistant to the mixed monolayer active conjugates. Furthermore, the bacteria 
that were resistant to one conjugate of nanoparticle were also resistant to all variants 
tested. Once resistance was activated, cellular adjustments within the bacterium conferred 
resistance to the various K. pneumoniae active conjugates, suggesting a similar mode of 
action for LAL-52 and LAL-32, as well as the altered feed ratio variants. 
The original conjugate LAL-32 with feed ratios of 33x, 46x, 33x for ligands 5, 6, 
8 respectively had an MIC99.9 of 0.625 μM and a time to resistance of 4 days. Decreasing 
the feed ratio of ligand 6 to 33x produced conjugate LAL-32 j, which was bactericidal at 
1.25 μM and doubled the time to resistance. Exchanging ligand 8 of LAL-32 for ligand 11 
produced LAL-52, which tripled the time to resistance. This experiment showed that both 
the identity and feed ratio of the thiol ligands significantly altered the antimicrobial effect 
of the conjugate, and the time to resistance. 
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Differential Gene Expression Experiment 
A differential gene expression experiment was performed to determine how the 
varying nanoparticle conjugates were affecting K. pneumoniae, and possibly further 
elucidate the mode of action of the gold nanoparticles. Analyzing the most altered genetic 
pathways by the nanoparticles may indicate how the conjugates were inhibiting bacterial 
growth. Samples of bacteria were incubated with conjugates LAL-32, LAL-32 j and 
LAL-52, as well as the pMBA-only capped conjugates. The inactive starting material 
control was utilized to investigate the impact of the gold core on the bacteria. An 
untreated bacteria control was utilized as a negative control to determine which genes 
were differentially expressed upon exposure to the gold nanoparticles. 
The bacteria were incubated for adequate time for the conjugates to be 
internalized into the cell, while remaining within the exponential growth phase.  Total 
RNA was extracted from the samples and sent to BGI Americas for RNA-Sequencing 
and bioinformatics. The differential gene expression analysis examined the quantity of 
each gene expressed in the conjugate-exposed samples compared to the bacteria-only 
control.  This analysis also assessed the gene expression levels in the active conjugate-
exposed samples compared to the pMBA-only control sample. Figure 2.2 shows the 
number of genes differentially expressed in each comparison. 
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Figure 2.2: The Number of Differentially Expressed Genes For LAL-32, LAL-32 j, 
and LAL-52 Gold Nanoparticle Conjugates Compared to a Bacteria-Only Control 
(No Treatment) as well as a pMBA-Only Gold Nanoparticle Control 
*Note: The reported differentially expressed genes (DEGs) have a False Discovery Rate (FDR) ≤ 0.001
and a | log2Ratio| ≥1 and are reported as statistically significant by BGI Americas. Figure from BGI 
Transcriptome Resequencing Report.  
Figure 2.2 shows that exposure to LAL-32 j up-regulated 239 genes in K. 
pneumoniae, whereas only 144 and 83 genes were up-regulated upon exposure to the 
LAL-32 and LAL-52 conjugates respectively. The gene expression analysis demonstrated 
the LAL-32 j conjugate affected gene expression in the bacteria significantly more than 
the original LAL-32 conjugate. Eighteen genes were affected by the pMBA-only inactive 
control particles, which suggested that the mixed thiol-ligand monolayer affected the 
majority of the differentially expressed genes. 
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Analysis of the Differentially Expressed Genes 
An extensive analysis was performed to determine how the nanoparticles were 
affecting the bacteria. In summary, a pathway analysis was performed to broadly 
determine which pathways were most affected by the nanoparticles. A Process Ontology 
evaluation was then performed to closely analyze some of the select pathways. The 
individual genes with the most differential expression were then examined to further 
analyze how the nanoparticles were altering gene expression. Genes that were common to 
all four nanoparticles, common to only the three active conjugates, as well as genes 
unique to LAL-32 j are discussed in this manuscript. 
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A. Pathway Analysis of the Differentially Expressed Genes 
A pathway analysis was performed to determine which biological pathways were 
most affected by the gold nanoparticles. Table 2.5 reports the pathways with the most 
significant quantity of differentially expressed genes (DEGs). 
Table 2.5: The Number of Differentially Expressed Genes (DEGs) Related to Select 
Biological Pathways Upon Exposure to Gold Nanoparticle Conjugates 
*Note: This is not a complete list of the differentially expressed genes. Pathways selected for reporting had
a large alteration or were of biological interest. An absolute value of Log2Ratio ≥1 was utilized as the 
threshold to judge the significance of differential gene expression. DEGs may exist within multiple 
categories. 
Pathway 
DEGs with 
LAL-32 j / 
Bacteria-Only 
(Percentage 
out of 209 
total) 
DEGs with 
LAL-32/ 
Bacteria-Only 
(Percentage 
out of 117 
total) 
DEGs with 
LAL-52/ 
Bacteria-Only 
(Percentage 
out of 80 
total) 
DEGs with 
pMBA-Only/ 
Bacteria-Only 
(Percentage 
out of 14 
total) 
Metabolic Pathways 47 (22.49%) 32 (27.35%) 15 (18.75%) 6 (42.86%) 
Biosynthesis of 
Secondary 
Metabolites 
30 (14.35%) 17 (14.53%) 11 (13.75%) 6 (42.86%) 
ABC Transporters 12 (5.74%) 7 (5.98%) 4 (5%) 0 
Phenylalanine 
Metabolism 11 (5.29%) 12(10.26%) 8 (10%) 0 
Tyrosine Metabolism 9 (4.31%) 6 (14.29%) 8 (10.39%) 1 (7.14%) 
Two Component 
System 8 (3.38%) 1 (0.85%) 4 (5%) 0 
Ribosome 7 (3.35%) 10 (8.55%) 6 (7.5%) 1 (7.14%) 
Glycolysis/ 
Gluconeogenesis 7 (3.35%) 4 (3.42%) 1 (1.25%) 2 (14.29%) 
Citrate Cycle (TCA) 5 (2.39%) 6 (5.13%) 0 5 (35.71%) 
Histidine Metabolism 0 0 4 (5.19%) 0 
The results in Table 2.5 indicated that the nanoparticles affected pathways relating 
to the biosynthesis of secondary metabolites and metabolism most significantly. 
Secondary metabolites are not directly involved in the normal growth or development of 
bacterial cells; however, they are usually produced in the late growth phase, and often 
39 
have antibiotic, pathogenic, or cellular differentiation properties.9 Metabolism includes 
all chemical reactions utilized to extract, convert and store energy from nutrients. The 
metabolic pathways were the most altered and were therefore selected for further 
analysis. 
I. Initial Metabolic Pathway Analysis Based on Ligand Structure 
 Some of the thiol ligands were chosen in part due to their similar structure to 
amino  acids.  Ligand  5  is  glutathione, a  tripeptide, ligand  6 is  a  degradation
product of cysteine, and ligand 11 is a thiolated histidine with a short polyethylene glycol 
linker. Phenylalanine and Tyrosine metabolism were both notably up-regulated by each 
of the active gold-nanoparticle conjugates. Figure 2.3 shows the similar structure between 
the pMBA molecule in the monolayer and the amino acids. 
Figure 2.3 The Structures of pMBA, Phenylalanine, and Tyrosine 
This large influx of amino-acid-like structures may have influenced the bacteria’s 
metabolism. LAL-52 contained the thiolated-histidine molecule, and was the only 
conjugate to up-regulate histidine metabolism. 
These amino-acid ligands may also mimic protein-protein interactions. Many 
transient protein complexes resemble receptor-ligand interactions, and are mediated by 
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protein interaction modules binding to short peptides exposed on the surface of target 
proteins.10 The interaction site and the target peptide are usually small. The nanoparticles 
may allow for competitive disruption of the complex and repression of the protein 
function.10 The bacteria may up-regulate metabolism in order to overcome the decrease in 
protein function. 
II. Initial Metabolic Pathway Analysis Based on Cell Stress
There is a possibility that the nanoparticles were causing environmental stress to 
the bacterial cells. It has been shown that antimicrobials cause a significant 
environmental impact on bacteria, which affect a variety of adaptive and protective 
responses. Bacteria modulate their gene expression patterns in response to environmental 
cues that allow the cells to adapt and survive. This modulation requires sensors to detect 
chemical or physical signals, and regulators to bring about changes in the levels of gene 
products, often in the form of a Two-Component Regulatory System.11 Table 2.5 reports 
that each active conjugate affected Two-Component Systems, which indicated that the 
bacteria were altering gene expression in response to environmental changes. The Two 
Component System Pathways were unaltered by the pMBA-only conjugates. This 
suggests that the presence of the gold-core in solution was not stimulating the adaptive 
changes in the bacteria; however, the antimicrobial active gold nanoparticle conjugates 
initiated the gene expression changes for survival.  
 Common adaptations as a result of environmental stress often include growth 
cessation or dormancy, changes to antimicrobial targets, alterations to the membrane 
barrier functions, generation of resistance mutations, or promotion of resistant growth 
modes, such as biofilms.12 The cells adjust to environmental changes by altering their 
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metabolism systematically.11 Metabolism includes a wide range of chemical processes, 
which is why a process ontology analysis was conducted to further examine the effects of 
the gold nanoparticles. 
B. Process Ontology to Further Analyze Metabolism Pathways 
A Process Ontology analysis was performed to more closely examine the 
biological processes affected by the nanoparticles. Table 2.6 lists the number of 
differentially expressed genes related to select biological processes. 
Table 2.6: The Number of Differentially Expressed Genes (DEGs) Related to Select 
Biological Processes Upon Exposure to Gold Nanoparticle Conjugates 
*Note: This is not a complete list of the differentially expressed genes. Processes selected for reporting had
a large alteration or were of biological interest. An absolute value of Log2Ratio ≥1 was utilized as the 
threshold to judge the significance of differential gene expression.  
Process 
Number of DEGs 
Related to Process 
LAL-32 j / 
Bacteria-Only 
 (165 total) 
Number of DEGs 
Related to Process 
LAL-32/ 
 Bacteria-Only 
 (93 total) 
Number of DEGs 
Related to Process 
 LAL-52/  
Bacteria-Only  
(66 total ) 
Metabolic Process 114 75 54 
Biosynthetic Process 36 25 27 
Oxidation Reduction 
Process 33 25 20 
Regulation of 
Biological Processes 28 10 4 
Transport 25 13 9 
Response to Stress 14 8 0 
Cellular Component 
Biogenesis 9 5 4 
Cell Division 6 2 0 
Response to Antibiotic 5 0 6 
Translation 5 9 5 
Cell Cycle 4 0 0 
Electron Transport 
Chain 3 0 2 
Cytokinesis 3 0 0 
Septum Assembly 2 0 0 
42 
The process ontology analysis confirmed that the majority of the DEGs were 
related to metabolic functions. However, it should be noted that many of the DEGs exist 
within multiple categories; numerous processes listed are sub-categories of metabolism. 
Figure 2.4  illustrates the  biosynthetic  processes and the oxidative  reduction  processes 
fall within the metabolic process category for the DEGs induced with exposure to LAL-
32 j. 
Figure 2.4 A venn diagram of the three major processes affected by DEGs in K. 
pneumoniae upon exposure to LAL -32 j compared to the bacteria-only control  
The three gold nanoparticle conjugates all appeared to affect a wide variety of 
metabolic pathways, but further analysis indicated that the metabolic changes were not 
identical with exposure to the different nanoparticle conjugates. When the differentially 
expressed genes in the metabolic process category from each active conjugate were 
compared, there was significant variation. Figure 2.5 shows the DEGs in the metabolic 
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process category induced upon exposure to the three different active gold nanoparticle 
conjugates. 
Figure 2.5: A venn diagram comparing the DEGs in the metabolic category induced 
upon exposure to the three different active gold nanoparticle conjugates.  
Although the pathway ontology data suggested that each gold nanoparticle 
significantly affected the metabolism of K. pneumoniae, Figure 2.5 illustrates the effects 
on metabolism vary with each conjugate.  The primary conclusions drawn from the 
Process Ontology report indicated that the biosynthetic processes, oxidation-reduction 
processes, transport, and regulation of biological processes were the main sub-category 
pathways affected by all nanoparticles. 
The data also indicated the expression of genes related to cell division were 
altered by LAL-32 j, but not LAL-32. LAL-32 j had the highest efficacy of inhibition out 
of the three conjugates and became bactericidal at 1.25 μM. This suggests that higher 
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efficacy nanoparticles may alter cell division more than nanoparticle conjugates with less 
antimicrobial efficacy. 
C. Individual DEG Analysis 
In order to better understand how the different nanoparticle conjugates were 
affecting the biological pathways, the individual genes with the highest levels of 
differentiation were analyzed. An absolute value of Log2(gene expression with treatment / 
gene expression no treatment) ≥ 1 was considered a statistically significant alteration in 
gene expression, and these genes were included in the pathway and process ontology 
analyses. However, for the individual gene analysis, DEGS with a Log2(treatment / 
control) ≥ 2 were selected in order to determine which genes had the most altered 
expression upon exposure to all of the gold nanoparticles. Table 2.7 lists DEGs with a 
Log2(treatment / control) ≥ 2 that were common to all of the gold-nanoparticle conjugates 
or all of the active conjugates.  
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Table 2.7: The Identification, Amount of Differentiated Gene Expression, and the 
Gene Product for Select Differentially Expressed Genes for the Gold Nanoparticle 
Conjugates Versus the Bacteria-Only Control 
*Note: This is not a complete list of the differentially expressed genes. Genes selected for reporting were
common to all four nanoparticle conjugates or the three active conjugates and had a 
|Log2(Treatment/Control)| ≥ 2. Some hypothetical proteins with no known function and 
|Log2(Treatment/Control)| ≤ 3 were emitted to minimize data size. The color scale aids in the identification 
of Up-Regulated (Red) and Down-Regulated (Green) genes. 
Gene ID 
Log2Ratio 
(pMBA-
Only/ 
Bacteria-
Only) 
Log2Ratio 
(LAL-32 j/ 
Bacteria-
Only) 
Log2Ratio 
(LAL-32/ 
Bacteria-
Only) 
Log2Ratio 
(LAL-52/ 
Bacteria-
Only) 
Gene Product 
kpn2146_RS06320 4.3292 6.4613 6.0517 5.5607 copper exporting ATPase 
kpn2146_RS16625 2.0174 5.4407 5.0302 4.6385 MerR family transcriptional regulator 
kpn2146_RS04600 1.7357 3.0565 2.5390 2.3954 multicopper oxidase 
kpn2146_RS09700 1.2623 2.1074 2.0791 1.2273 membrane protein; OmpA; Porin 
kpn2146_RS11060 4.4607 1.9399 3.1191 
hypothetical protein - belongs to a family involved 
in Cell wall/membrane/envelope biogenesis 
kpn2146_RS26690 4.0572 2.7144 2.0315 glycerol uptake facilitator GlpF 
kpn2146_RS04105 4.0545 3.8617 2.7521 
hypothetical protein - periplasmic protein induced 
by stress response via Cpx and BaeSR system 
kpn2146_RS17280 3.7335 1.6698 2.2814 membrane protein 
kpn2146_RS15405 3.3854 1.2197 1.9092 hypothetical protein 
kpn2146_RS06995 3.2401 3.1854 2.4998 hypothetical protein 
kpn2146_RS11370 3.0505 2.4586 2.2201 hypothetical protein 
kpn2146_RS10405 3.0337 2.9017 2.2289 hypothetical protein 
kpn2146_RS03410 3.0217 1.2218 1.6827 porin 
kpn2146_RS09395 2.8932 1.9523 2.0411 lipoprotein chaperone 
kpn2146_RS17190 2.7529 1.1743 1.4875 heat shock protein HtpX 
kpn2146_RS12445 2.7345 2.8770 2.1903 enoyl-CoA hydratase 
kpn2146_RS25775 2.5802 1.3769 2.0182 zinc/cadmium/mercury/lead-exporting ATPase 
kpn2146_RS08735 2.5244 1.6200 1.2321 outer membrane protein X 
kpn2146_RS17335 2.5224 1.9638 1.2818 zinc ABC transporter substrate-binding protein 
kpn2146_RS12435 2.3846 2.4332 2.3369 phenylacetic acid degradation protein 
kpn2146_RS12390 2.3739 2.1352 1.6006 aldehyde dehydrogenase 
kpn2146_RS25545 2.3341 1.8734 1.1519 glycerol-3-phosphate dehydrogenase 
kpn2146_RS12420 2.2712 1.6891 2.3235 phenylacetate-CoA oxygenase subunit PaaB 
kpn2146_RS21520 2.2490 1.0193 1.3690 iron ABC transporter substrate-binding protein 
kpn2146_RS00385 2.2044 1.1839 1.2361 repressor CpxP 
kpn2146_RS23680 2.1749 1.5348 1.1332 membrane protein 
kpn2146_RS08600 2.1162 1.3974 1.0425 membrane protein 
kpn2146_RS09400 2.0276 1.4093 1.4106 recombinase RarA 
kpn2146_RS22810 1.9490 2.5118 1.3509 glycine cleavage system protein H 
kpn2146_RS22510 -2.5763 -1.1859 -2.3811 ferrous iron transporter B involved in uptake 
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I. DEGs Common to All Four Gold Nanoparticles 
All four gold nanoparticles tested, including the inactive pMBA-capped 
conjugates, caused an up-regulation of membrane porins, the MerR family of 
transcriptional regulators, and Copper-Exporting ATPase. The majority of regulators in 
the MerR family activate transcription in response to environmental stimuli such as 
oxidative stress, heavy metals or antibiotics.13 The inactive pMBA-capped nanoparticles 
caused an up-regulation of this transcription regulator, and was further up-regulated in 
the presence of the active antimicrobial conjugates. Experiments have shown that 
oxidative stress and copper resistance gene clusters are induced in bacteria living in 
metal-contaminated environments, conceivably to promote cellular defense.14 This 
suggests that the inactive gold core alone may cause K. pneumoniae to induce a cellular 
protection response, even though the pMBA-capped gold nanoparticles have no 
inhibitory effects on the growth of the bacteria.15  
II. DEGs Common to All Three Active Conjugates
All three of the active conjugates induced an up-regulation of various porins, 
transcriptional regulators, stress response proteins, and transporters. Many transporters 
dedicated to the export of metals were up-regulated including a 
zinc/cadmium/mercury/lead-exporting ATPase, a zinc ABC transporter substrate-binding 
protein and an iron ABC transporter substrate-binding protein. One of the most down-
regulated proteins was ferrous iron transporter B, involved in uptake of iron. The 
differential expression of these transport systems indicated that the bacteria were 
attempting to remove the heavy metals, which could include the gold nanoparticles. 
A large number of proteins, lipoproteins, and enzymes related to the cell 
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membrane were among the most up-regulated genes. Select genes include kpn2146-
RS11060, a protein involved in cell envelope biosynthesis, and kpn2146_RS09395,
which encodes for lolA, and interacts with lolB to transfer lipoproteins from the cytosolic 
membrane to the outer membrane.16 The up-regulation of these genes may indicate that 
the nanoparticles caused an alteration in the cell membrane. In addition, 
kpn2146_RS25545, encoding for glycerol-3-phosphate dehydrogenase and 
kpn2146_RS26690, encoding for glycerol uptake facilitator GlpF were up-regulated. 
These genes may be involved in phospholipid and other cellular component biosynthesis. 
Glycerol and glycerol-3-phosphate are precursors for phospholipid biosynthesis, as well 
as other essential cellular components, such as the cell wall.17 Glycerol-3-phosphate 
dehydrogenase is an essential membrane enzyme, functioning at the central junction of 
respiration, glycolysis, and phospholipid biosynthesis.17 The up-regulation of these genes, 
combined with previous knowledge that the three gold nanoparticle conjugates inhibit 
bacterial growth, indicated that the gold nanoparticle conjugates may be affecting cellular 
component biosynthesis required for cell division or proliferation. This evidence also 
indicated that the conjugates might significantly affect integrity of the cell membrane. 
A number of genes related to the envelope stress response pathway were up-
regulated. The disruption of normal protein trafficking in the cell envelope activates the 
Cpx Pathway.18 This activation stimulates the expression of a number of genes whose 
products function to fold or degrade the delocalized proteins. All three active conjugates 
caused an up-regulation of kpn2146_RS17190, encoding for the heat shock protein HtpX. 
HtpX is a zinc metalloprotease that collaborates with FtsH to degrade abnormal 
membrane proteins.18 HtpX is under control of the Cpx Envelope Stress Response. 
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kpn2146-RS04105, a periplasmic protein induced by the cell envelope response pathway, 
was also up-regulated by all three active conjugates. However, all three active conjugates 
up-regulated kpn2146_RS00385, which produced Repressor CpxP. Repressor CpxP is a 
small protein that blocks a regulon controlling the Cpx two component system.19 
Overexpression of the repressor can block activation of the pathway.19 The Cpx two 
component regulatory system plays an important role in protection from stresses, and the 
repression of the pathway can lead to reduced cell survival.19  
The gene expression experiments indicated that all three conjugates may be up-
regulating various transporters in an attempt to remove heavy metals. All three active 
conjugates may also be repressing the Cpx cell envelope response. A large proportion of 
the most up-regulated genes were implicated in cell membrane pathways; however, 
further experimentation is required to determine exactly how the bacterial membrane is 
affected by the gold nanoparticle conjugates. 
III. DEGs Unique to LAL-32 j
The genes listed in Table 2.7 were the genes most up-regulated and common to all 
of the nanoparticle conjugates. They were analyzed to determine how the nanoparticles 
generally affected the bacteria. It was also of interest to determine which genes were 
differentially expressed only upon exposure to LAL-32 j and not by other conjugates. 
LAL-32 j was found to inhibit more bacterial growth than the original LAL-32 
compound, and became bactericidal at 1.25 μM. LAL-32 j also doubled the time of 
resistance over the original formulation. LAL-32 affected 151 genes when incubated with 
K. pneumonia, whereas LAL-32 j altered the expression of 299 genes. The approximate 
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doubling in gene expression was attributed to altering the feed ratio of ligand 6, as this 
was the only difference between the two compounds. Figure 2.6 compares the genes 
differentially expressed by each nanoparticle conjugate. 
Figure 2.6: A venn diagram comparing the genes differentially expressed upon 
exposure to each of the nanoparticle conjugates versus the bacteria-only control. 
Figure 2.6 illustrates 162 genes unique to conjugate LAL-32 j. Due to the large 
number of unique genes, only certain processes were selected for detailed analysis.  It 
was of interest to determine how LAL-32 j more effectively inhibited the growth of the 
bacteria compared to LAL-32. The process gene ontology reported that LAL-32 j caused 
differential expression in genes related to stress response, cell division, response to 
antibiotics, and the cell cycle, many of which were not differentially expressed upon 
exposure to LAL-32. A set of unique genes was selected from these processes to further 
understand how the LAL-32 j conjugate increased the efficacy of bacterial growth 
inhibition. 
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Table 2.8: The Identification, Amount of Differentiated Gene Expression, and the 
Gene Product for Genes Differentially Expressed in LAL-32 j Relating to Cell 
Division, the Response to Antibiotics, or Response to Stress 
*Note: This is not a complete list of the differentially expressed genes. Genes selected for reporting were
differentially expressed upon exposure to LAL-32 j, but not differentially expressed upon exposure to 
LAL-32. The genes reported are implicated in processes concerning cell division, the cell cycle, response to 
stress, and response to antibiotic.  An absolute value of Log2(Treatment/Control) ≥ 1 was used to determine 
statistical significance. The color scale aids in the identification of Up-Regulated (Red) and Down-
Regulated (Green) genes. 
Gene ID Log2Ratio (LAL-32 j/ Bacteria-Only) Gene Product 
kpn2146_RS04340 1.4050 cell division protein MraZ 
kpn2146_RS22840 1.7213 Z-ring-associated protein 
kpn2146_RS19485 1.3161 cell division protein ZipA 
kpn2146_RS21680 1.1885 cell division protein FtsB 
kpn2146_RS09390 1.1599 cell division protein FtsK 
kpn2146_RS02925 -1.1833 integrase 
kpn2146_RS23455 -1.0188 transposase 
kpn2146_RS23140 -1.0359 integrase 
kpn2146_RS02930 -1.1948 integrase 
kpn2146_RS25830 1.9419 UDP phosphate 4-deoxy-4-formamido-L-arabinose transferase 
kpn2146_RS15400 1.8503 beta-lactamase 
kpn2146_RS13160 1.4617 beta-lactamase 
kpn2146_RS25835 1.5363 UDP-4-amino-4-deoxy-L-arabinose-oxoglutarate aminotransferase 
kpn2146_RS20935 1.3404 putative multidrug efflux system membrane fusion component OqxA 
kpn2146_RS25825 1.1599 bifunctional UDP-glucuronic acid decarboxylase/UDP-4-amino-4-deoxy-L-arabinose formyltransferase 
kpn2146_RS09340 1.4609 cold-shock protein – inhibits DNA replication 
kpn2146_RS09680 1.1094 ribosome modulation factor 
kpn2146_RS07755 1.4195 universal stress protein G – associates with GroEL 
kpn2146_RS11520 1.1709 dihydropteroate synthase 
kpn2146_RS11115 1.0253 hydroperoxidase II 
kpn2146_RS14455 1.0154 peroxiredoxin 
kpn2146_RS02080 -1.0422 colicin V secretion protein CvaA 
kpn2146_RS01605 -1.0812 anti-adapter protein iraM – Stabilizes RpoS 
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i. DEGs Unique to LAL-32 j Involved in Cell Division
Various cell-division proteins were differentially expressed with LAL-32 j, but 
were not expressed in LAL-32. These proteins included MraZ, a Z-ring associated 
protein, ZipA, and FtsB. MraZ plays a role in cell-wall biosynthesis and cell division.20 
FtsB is implicated in the septum-localization process during cell division.21 The cell 
division protein FtsZ is anchored to the cytoplasmic membrane by the membrane protein 
ZipA.22 The up-regulation of these cell division proteins may indicate the bacteria 
attempting to overcome a block in cell division caused by the gold nanoparticles. The 
FtsK gene was also up-regulated, which is an essential cell division protein that localizes 
at the septum. It is induced by the SOS response, a reaction to DNA damage where the 
cell cycle is arrested.23 A SOS-inducible promoter precedes the FtsK gene, and the 
overexpression of FtsK has been shown to block cell division.23 The additional effects on 
the cell division proteins seen with LAL-32 j, but not the other conjugates, may be an 
insight into why the efficacy of inhibition was significantly increased with the altered 
feed ratio conjugate. Additional experimentation is required to determine exactly how the 
LAL-32 j conjugate affected cell division. 
ii. DEGs Unique to LAL-32 j Involved in Oxidative Stress
LAL-32 j also caused the up-regulation of peroxiredoxin, and hydroperoxidase II. 
These enzymes help protect the cell from oxidative stress induced by hydrogen peroxide. 
Bacteria such as K. pneumoniae that grow aerobically utilize molecular oxygen (O2) for 
respiration or oxidation of nutrients.24 By-products of the reactions include superoxide 
anion radicals (·O2–), hydrogen peroxide (H2O2), and the highly reactive hydroxyl radicals 
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(·OH), and are generated continuously as cells grow.24 The LAL-32 j compound affected 
144 metabolic genes, 33 oxidation-reduction genes, and 3 genes involved in the electron 
transport chain. The large up-regulation in metabolism, with presumably decreased 
regulation, may cause a large increase in the production of reactive oxygen species. The 
biological targets for these highly reactive molecules are DNA, RNA, proteins and 
lipids.24 Lipids are a major target during oxidative stress, and the free radicals can directly 
attack polyunsaturated fatty acids in the membrane, which initiate peroxidation in the 
cell.24 Lipid peroxidation decreases membrane fluidity, altering membrane properties, and 
may disrupt membrane-bound proteins.24 An amplification process is initiated in the 
bacteria when the polyunsaturated fatty acids are degraded to products such as aldehydes, 
which themselves are very reactive and can damage molecules such as proteins.24 The 
differential gene expression data indicated that each nanoparticle conjugate may have 
caused a large alteration in the bacteria membrane, which may be partially explained by 
the production of reactive oxygen species.  The unique up-regulation of the peroxiredoxin 
and hydroperoxidase II genes by LAL-32 j may indicate that the LAL-32 j could have 
induced additional forms of oxidative stress on the cell through the production of a 
reactive oxygen species. 
iii. DEGs Unique to LAL-32 j Involved in Antibiotic Resistance
LAL-32 j uniquely induced the differential expression of a significant number of 
antibiotic resistance genes. The nanoparticle conjugate caused the up-regulation of beta-
lactamases, the enzyme that confers resistance to beta-lactam antibiotics, including 
carbapenems. A multidrug efflux system membrane fusion component OqxA was up-
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regulated, as well as numerous UDP genes targeted for the resistance mechanism for 
polymyxin and cationic antimicrobial peptides. The up-regulation of these antibiotic 
resistant pathways indicated that the bacterial antibiotic resistance genes had been 
induced, while the bacteria remained susceptible to the gold nanoparticle conjugates for 
nine days. The bacteria did not up-regulate any of these genes when exposed to LAL-32, 
which possibly indicated that LAL-32 did not have the same antibiotic threat level to the 
bacteria, and thereby failed to initiate the resistance pathways. 
LAL-32 j doubled the time to resistance over LAL-32 in K. pneumoniae. This 
increase in time to resistance may be attributed to the down regulation of integrases and 
transposases upon exposure to the LAL-32 j conjugate. These genes remained unaffected 
after incubation with LAL-32.  Transposases and integrases are proteins that mediate the 
recombination reaction in which discrete DNA segments are transferred between 
nonhomologous sites.25 Many antibiotic resistance genes are encoded on plasmids or 
transposons, and can be transferred to other bacteria.26 The horizontal gene transfer of 
antibiotic resistance has led to wide-spread resistance as well as multi-drug resistant 
pathogens. The down-regulation of the integrases and transposases upon incubation with 
LAL-32 j indicated that the feed ratio of the thiol ligands in the monolayer might affect 
resistance mechanisms, as well as the dissemination of antibiotic resistant genes. 
There is a possibility that the down-regulation of the integrase and transposase 
genes was attributed to the splicing of the cassette from the replicative chromosome in an 
action to transfer the genes to another bacterium. If the bacteria were up-regulating genes 
for widespread resistance after four hours of incubation with the gold-nanoparticles, it 
would imply that the bacteria do not possess the gene cassettes necessary for gold-
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nanoparticle resistance. The bacteria remained susceptible to the gold-nanoparticle 
conjugates for nine days with sub-inhibitory concentrations of treatment.
LAL-32 j was created by taking the LAL-32 conjugate designed for E. coli, and 
decreasing the feed ratio of ligand 6. This resulting conjugate was able to overcome the 
extracellular polysaccharide capsule of K. pneumoniae and became bactericidal at 1.25 
μM. Bactericidal compounds that kill the microbes instead of inhibiting growth may aid 
in the avoidance of antibiotic resistance, since they decrease the number of bacteria 
available to undergo a spontaneous genetic mutation allowing for antibiotic resistance. 
LAL-32 j induced the differential expression of 299 genes in K. pneumoniae versus the 
151 genes differentially expressed with LAL-32. The much larger increase in gene 
expression may indicate that the LAL-32 j more significantly affected the bacteria. 
LAL-32 j Tested Against M. avium and M. Abscessus 
An experiment was then performed to determine if LAL-32 j was effective against 
Mycobacterium avium (MAC 104WT) and Mycobacterium abscessus (ATCC 19977). 
These bacteria are opportunistic pathogens and contain a thicker cell wall coated by a 
waxy, hydrophobic, mycolic acid layer.27 This mycolic acid layer makes it difficult for 
many compounds, including antibiotics, to reach intracellular targets. The LAL-32 j 
compound was tested against M. avium and M. abscessus in concentrations up to 10 μM. 
All samples tested were turbid upon visual analysis, and plating and colony counting 
found no significant levels of bacterial growth inhibition at concentrations tested. 
The Feldheim Lab showed that both the identity of ligands and their feed ratios in 
the monolayer of the gold nanoparticle greatly affected the antimicrobial properties of the 
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nanoparticle.6 The feed ratio of ligand 6 turned one of the E. coli conjugates into a 
conjugate highly active toward K. pneumoniae. This conjugate however, was ineffective 
against M. avium and M. abscessus. It is possible that the gold-nanoparticles are narrow-
spectrum antibiotics. Narrow spectrum antibiotics are only effective against a certain 
bacteria, or group of bacterium, and are administered when the causative agent of the 
infection is known.28 One benefit of narrow-spectrum antibiotics are that they cause less 
antibiotic resistance because they deal only with specific bacteria.28 Further 
experimentation is required to determine which bacterial species may be affected by 
LAL-32 j. 
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IIII. Conclusion
The nanoparticle conjugates previously designed for E. coli were effective 
inhibitors against K. pneumoniae. LAL-32 and LAL-52 had the lowest MIC99.9 of 0.625 
μM and were therefore chosen for further testing. LAL-32 had feed ratios of 33x, 46x, 
and 33x for ligands 5, 6 and 8 respectively. Altering the feed ratio of ligand 6 to 33x 
produced conjugate LAL-32 j, which became bactericidal at 1.25 μM. LAL-32 j was also 
able to double the time to resistance over the original LAL-32 conjugate. K. pneumoniae 
took twelve days to become resistant to LAL-52, which had feed ratios of 33x, 46x, and 
16.5x for ligands 5, 6 and 11  respectively. These experiments indicated that the ratio and 
identity of the thiol ligands in the monolayer greatly affect the antimicrobial efficacy and 
the time to resistance for the nanoparticles. The resistance assay also indicated that 
bacteria that are continually exposed to the inactive pMBA-capped nanoparticles remain 
sensitive to the active conjugates. Bacteria that were resistant to one conjugate were also 
resistant to all variants tested, indicating a similar mode of action for LAL-52 and LAL-
32, as well as the altered feed-ratio variants. 
The differential gene expression experiment demonstrated that LAL-32 j 
significantly affected a greater number of genes than the original conjugate LAL-32. 
Gold nanoparticles with greater antimicrobial efficacy may affect the bacteria more than 
the less active conjugates. The gene expression assay also indicated that the pMBA-
capped nanoparticles affected the expression of only eighteen genes in the K. 
pneumoniae. The pMBA-capped nanoparticles up-regulated genes implicated with 
environmental heavy metals, but had no effect on the growth of the bacteria. This 
increase in gene expression implied that the mixed-ligand monolayer conjugates 
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primarily inhibit the growth of the bacteria, and the sole presence of the gold core did not 
considerably affect the bacteria. 
Each of the three active conjugates tested greatly altered the expression of 
bacterial metabolism, and the genes implicated in the structure of the cell membrane in 
slightly different ways. Additional experimentation is required to determine how the 
nanoparticles are affecting the bacteria. The conjugate with the most antimicrobial 
efficacy, LAL-32 j, also affected a number of cell division and antibiotic resistance 
pathways. The antibiotic resistance pathways were induced in the bacteria after four hours 
of incubation with LAL-32 j, but the bacteria remained sensitive to the conjugate for nine 
days. This experiment implied that the innate antibiotic resistance genes present in the K. 
pneumoniae strain were not able to overcome the gold nanoparticles. 
The gold nanoparticle conjugate LAL-32 j was found to be ineffective against M. 
avium and M. abscessus. This may indicate that the gold nanoparticles are narrow 
spectrum antibiotics; however, further experimentation is required to determine which 
bacteria are sensitive to the LAL-32 j conjugate. LAL-32 j demonstrated the possibility 
for the gold nanoparticles to delay the onset of antibiotic resistance. LAL-32 j doubled 
the time to resistance over the original LAL-32 compound, and is bactericidal at 1.25 
μM. Bactericidal compounds decrease the overall number of cells, and therefore the 
probability of a spontaneous genetic mutation to confer antibiotic resistance. If LAL-32 j 
is specific toward certain bacterial groups, it may aid in the problem of multi-drug 
resistant pathogens. Bacteria unaffected by the gold nanoparticles would not likely gain 
nor pass on resistant genes. These experiments demonstrated that the identity and ratio of 
ligands in the monolayer of the gold nanoparticle affect the antimicrobial efficacy of the 
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conjugate as well as the time to resistance. The active gold nanoparticle conjugates may 
be further improved by altering the ligands in the monolayer to further avoid the serious 
problem of antibiotic resistance. 
